- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozymeâ"¢ technology. Under the terms of the agreement, Biogen will obtain exclusive rights ...

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic ...

BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of the certification of a class action on behalf of purchasers of BioGen, Inc. securities (NASDAQ: BIIB): UNITED STATES DISTRICT COURTDISTRICT OF MASSACHUSETTS Oklahoma Firefighters pension and retirement system,               Plaintiff,  Civil Action No. 1:22-cv-10200-WGY     v.   BIOGEN INC., MICHEL VOUNATSOS, AND ALISHA A ...

Core Insights - Biogen Inc. is set to present late-breaking data on litifilimab's efficacy in treating cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology Annual Meeting, highlighting its potential as a first-in-class monoclonal antibody targeting BDCA2 [1][2] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on innovative science to develop new medicines and create value for shareholders and communities [10] Product Development - Litifilimab (BIIB059) is a humanized IgG1 monoclonal antibody targeting BDCA2, currently under investigation for the treatment of systemic lupus erythematosus (SLE) and CLE [5][6] - The AMETHYST study is a two-part, Phase 2/3 multicenter, double-blind, placebo-controlled trial assessing the efficacy and safety of litifilimab in patients with active subacute and chronic CLE who are refractory or intolerant to antimalarial therapy [4][6] Regulatory Status - The U.S. FDA has granted litifilimab Breakthrough Therapy Designation for CLE, supported by results from the Phase 2 AMETHYST study and the Phase 2 LILAC study [2][6] Clinical Insights - The upcoming presentation will include 24-week results from the Phase 2 study, showcasing the safety and efficacy of litifilimab in treating CLE [3][6] - CLE is a serious autoimmune disease that can lead to significant quality of life impacts, with no approved targeted therapies available since the 1950s [9]

PresentationPaul MatteisStifel, Nicolaus & Company, Incorporated, Research Division Great. Thanks very much. This is going to be an interesting 45-minute discussion on a number of topics within the Biogen pipeline. With me is Diana Gallagher, Head of Clinical Development; and Stephanie Fradette, Head of the Neuromuscular Development Unit. Maybe just you can each of you just sort of briefly introduce yourselves, how long you've been at Biogen, and then we can get right into it. I think I wanted to start with ...

Summary of Biogen Conference Call Company Overview - **Company**: Biogen - **Key Personnel**: - Diana Gallagher, Head of Clinical Development (11 years at Biogen) - Stephanie Fradette, Head of Neuromuscular Development Unit (16 years at Biogen) Key Topics Discussed Tau and Alzheimer's Disease - **Tau as a Target**: Tau is considered a significant target in Alzheimer's disease, being one of the two pathological hallmarks alongside amyloid. The emergence of tau pathology correlates closely with cognitive decline, more so than amyloid prevalence [6][7] - **Clinical Trials**: The CELIA trial aims to establish proof of concept for tau reduction using the ASO approach (BIIB080) over 18 months, assessing its impact on clinical endpoints [8][18] - **Safety Considerations**: A reduction of up to 50% in tau levels may not lead to gross neurological effects, and the company is testing various doses to ensure safety and tolerability [10][11] - **Efficacy Concerns**: The relationship between tau reduction and clinical efficacy remains uncertain, and the trial is designed to explore this [17][19] Pre-Symptomatic Alzheimer's Studies - **AHEAD 3-45 Study**: This study targets pre-symptomatic patients with an amyloid burden greater than 40 centiloids, aiming to prevent cognitive decline. It uses the PACC5 endpoint to detect cognitive changes [34][35] - **Comparative Analysis**: The study design differs from TRAILBLAZER-ALZ 3, which focuses on patients at a tipping point of cognitive decline. Positive results from AHEAD 3-45 could provide insights into the efficacy of anti-amyloid therapies in pre-symptomatic patients [36][40] Neuromuscular Development - **Salanersen**: An investigational ASO designed for once-yearly dosing, showing promise in a phase 1b study with generally well-tolerated results. The study focused on safety and exploratory outcomes rather than powered efficacy [49][51] - **Phase 3 Studies**: Three phase 3 studies are planned, including STELLAR-1 for treatment-naive presymptomatic infants and STELLAR-2 for those who received gene therapy. These studies aim to establish salanersen's effectiveness compared to existing therapies [55][56] Lupus Treatment - **Litifilimab**: A drug targeting BDCA2, with phase 2 studies showing promise in skin and joint effects in lupus patients. The transition to phase 3 studies involves a larger patient population to validate efficacy [63][64] - **DAPI Study**: A phase 3 study that successfully hit primary endpoints and showed meaningful improvements in fatigue and steroid tapering, indicating a significant impact on lupus symptoms [74][75] Future Directions - **Pipeline Development**: Biogen is focused on developing next-generation therapies across various conditions, including Alzheimer's and SMA, while ensuring patient convenience and efficacy [30][31] - **Commercial Viability**: The company acknowledges the challenges in treating pre-symptomatic patients but sees potential in blood-based biomarkers and easier administration routes to facilitate broader access [44][48] Additional Insights - **Market Readiness**: The company is optimistic about the evolving landscape for treating pre-symptomatic Alzheimer's patients, emphasizing the need for improved diagnostics and treatment pathways [43][46] - **Differentiation in SMA**: Salanersen aims to provide a differentiated approach in the SMA landscape, with a focus on achieving efficacy comparable to high-dose Spinraza while reducing dosing frequency [54][60] This summary encapsulates the key points discussed during the conference call, highlighting Biogen's strategic focus on innovative therapies and the ongoing development of its pipeline across various therapeutic areas.

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook compared to the overall market performance [6][11]. Core Insights - Recent adjustments to the Hong Kong Stock Connect list include companies like Weili Zhibo and Jinfang Pharmaceutical, effective from March 9, 2026. Additionally, Kangfang Biotech's first tri-antibody has received clinical trial approval [2][3]. - Kingsray Biotech expects an adjusted net profit of USD 207-242 million for 2025, representing a year-on-year growth of approximately 246.5%-304.3%, primarily driven by licensing revenue growth from USD 2.4 million in 2024 to USD 256-299 million [2][7]. - The Hang Seng Healthcare Index rose by 2.58%, outperforming the Hang Seng Index by 1.02 percentage points [6]. Summary by Sections 1. Overseas Pharmaceuticals - Companies like Weili Zhibo and Jinfang Pharmaceutical have been included in the Hong Kong Stock Connect list, effective March 9, 2026. Kangfang Biotech's AK150 has received clinical trial approval for treating advanced malignant solid tumors [3][8]. - Songli Pharmaceutical's small molecule GLP-1R agonist ASC30 achieved statistically significant weight loss results in a U.S. Phase II trial, with an average weight reduction of 7.5% after three monthly doses [3][8]. 2. Performance Updates - Kingsray Biotech anticipates a significant increase in net profit for 2025, while Lepu Biotech expects to achieve a net profit of no less than RMB 200 million, marking a turnaround from losses [2][7]. - Jike Si's revenue is projected to decline by 65.6% in 2025, with a net loss of RMB 146 million [2][7]. 3. Recommendations - The report suggests focusing on innovative drugs with ongoing commercialization and business development opportunities, particularly companies like Baijie Shenzhou, Xinda Biotech, and Kangfang Biotech [11]. - In the pharmaceutical sector, companies like Sanofi and China Biopharmaceutical are highlighted for their progressive innovation pipelines [11]. 4. Overseas Education - The education index increased by 3.1%, outperforming the Hang Seng China Enterprises Index by 0.3 percentage points [13]. - The report recommends focusing on Chinese Oriental Education, which is expected to see accelerated enrollment growth due to rising demand for vocational training [15]. 5. Overseas Social Services - Macau's total visitor numbers during the Spring Festival reached a record high, with 1.554 million visitors and an average daily visitor count of 173,000, reflecting a year-on-year growth of 5.5% [17].

Investment Rating - The industry investment rating is "Overweight" indicating that the industry is expected to outperform the overall market [2][6]. Core Insights - Recent adjustments to the Hong Kong Stock Connect list include companies such as Weili Zhibo and Jinfang Pharmaceutical, effective from March 9. Kangfang Biologics has received clinical approval for its first tri-antibody [2][3]. - Kingsray Biotech anticipates an adjusted net profit of USD 207-242 million for 2025, representing a year-on-year growth of approximately 246.5%-304.3%, primarily due to licensing revenue increasing from USD 2.4 million in 2024 to USD 256-299 million [2][7]. - The Hang Seng Healthcare Index rose by 2.58%, outperforming the Hang Seng Index by 1.02 percentage points [6]. Summary by Sections 1. Overseas Pharmaceuticals - Companies like Weili Zhibo, Jinfang Pharmaceutical, and others have been included in the Hong Kong Stock Connect list since March 9. Kangfang Biologics' AK150 has received clinical trial approval for treating advanced malignant solid tumors [3][8]. - Alnylam has initiated a clinical trial for ALN-2232 (ALK7 siRNA) aimed at obesity, with an expected completion date in March 2028 [4][9]. - Agilent Technologies has agreed to acquire Biocare Medical for USD 950 million, enhancing its capabilities in clinical pathology [4][9]. 2. Performance Updates - Kingsray Biotech expects a significant increase in net profit for 2025, while Lepu Biotech anticipates a net profit of no less than RMB 200 million, marking a turnaround [7][8]. - The revenue forecast for Jike Si is projected to decline by 65.6% in 2025, with a net loss of RMB 146 million [7][8]. 3. Recommendations - Focus on innovative drugs with ongoing commercialization and active overseas transactions, particularly companies like BeiGene, Innovent Biologics, and Kangfang Biologics [12]. - In the Pharma sector, companies like 3SBio and Hansoh Pharmaceutical are making strides in their innovative pipelines [12]. 4. Education Sector - The education index increased by 3.1%, outperforming the Hang Seng Index by 0.3 percentage points [14]. - China Oriental Education is recommended due to its strong growth prospects and strategic adjustments in response to vocational training demand [17]. 5. Social Services - Macau's visitor numbers during the Spring Festival reached historical highs, with total inbound travelers at 1.554 million and an average daily visitor count of 173,000, reflecting a year-on-year growth of 5.5% [19].

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]

Company Overview - Biogen Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on therapies for neurological and neurodegenerative diseases, with a market cap of $27.7 billion [1]. Market Position - Biogen is classified as a large-cap stock, with its market cap exceeding $10 billion, highlighting its size and influence in the drug manufacturing industry [2]. - The company is expanding its pipeline into immunology and rare diseases, utilizing advanced modalities like antisense oligonucleotides (ASOs) to meet significant medical needs [2]. Stock Performance - Currently, Biogen's shares are trading 5.5% below their 52-week high of $202.41, reached on February 6 [3]. - Over the past three months, Biogen's shares have increased by 10.8%, outperforming the State Street Health Care Select Sector SPDR ETF (XLV), which experienced a slight decline [3]. - Year-to-date, Biogen's shares are up 8.6%, while XLV has fallen by 1.4% [5]. - In the last 52 weeks, Biogen's stock has surged by 33.1%, significantly outpacing XLV's 4.6% increase [5]. Earnings Performance - Following a stronger-than-expected Q4 earnings release on February 6, Biogen's shares rose by 8.5% [7]. - The company's revenue for Q4 was $2.3 billion, a 7.1% decline year-over-year, but it exceeded the analyst estimate of $2.2 billion [7]. - Adjusted EPS for the quarter was $1.99, surpassing consensus expectations of $1.63, attributed to strong performance from newer products like Leqembi, Skyclarys, Zurzuvae, and Qalsody, which collectively generated over $1 billion in annual revenue [7]. Competitive Analysis - Biogen has outperformed its competitor Amgen Inc. (AMGN), which saw an 18.4% increase over the past 52 weeks, although Biogen has lagged behind AMGN's 15.3% year-to-date rise [8]. - Analysts maintain a moderately optimistic outlook for Biogen, with a consensus rating of "Moderate Buy" from 35 analysts and a mean price target of $206.66, indicating an 8.6% premium to current price levels [8].